|
|
||||||||
1Department of Physiology, Medical College of Georgia, Augusta, Georgia; 2Department of Entomology and Cancer Center, University of California, Davis, California; 3Second Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong Province, People's Republic of China; 4Division of Nephrology, University of Utah and Veterans Affairs Medical Center, Salt Lake City, Utah; and 5Departments of Biochemistry and Pharmacology, University of Texas Southwestern Medical Center, Dallas, Texas
Submitted 3 January 2007 ; accepted in final form 10 April 2007
Since epoxyeicosatrienoic acids (EETs) affect sodium reabsorption in renal tubules and dilate the renal vasculature, we have examined their effects on renal hemodynamics and sodium balance in male rats fed a high-fat (HF) diet by fenofibrate, a peroxisome proliferator-activated receptor-
(PPAR-
) agonist and an inducer of cytochrome P-450 (CYP) epoxygenases; by N-methanesulfonyl-6-(2-proparyloxyphenyl)hexanamide (MSPPOH), a selective EET biosynthesis inhibitor; and by 12-(3-adamantane-1-yl-ureido)dodecanoic acid (AUDA), a selective inhibitor of soluble epoxide hydrolase. In rats treated with fenofibrate (30 mg·kg1·day1 ig) or AUDA (50 mg/l in drinking water) for 2 wk, mean arterial pressure, renal vascular resistance, and glomerular filtration rate were lower but renal blood flow was higher than in vehicle-treated control rats. In addition, fenofibrate and AUDA decreased cumulative sodium balance in the HF rats. Treatment with MSPPOH (20 mg·kg1·day1 iv) + fenofibrate for 2 wk reversed renal hemodynamics and sodium balance to the levels in control HF rats. Moreover, fenofibrate caused a threefold increase in renal cortical CYP epoxygenase activity, whereas the fenofibrate-induced elevation of this activity was attenuated by MSPPOH. Western blot analysis showed that fenofibrate induced the expression of CYP epoxygenases in renal cortex and microvessels and that the induction effect of fenofibrate was blocked by MSPPOH. These results demonstrate that the fenofibrate-induced increase of CYP epoxygenase expression and the AUDA-induced stabilization of EET production in the kidneys cause renal vascular dilation and reduce sodium retention, contributing to the improvement of abnormal renal hemodynamics and hypertension in HF rats.
obesity; cytochrome P-450; arachidonic acid; eicosanoid; kidney
This article has been cited by other articles:
![]() |
A. A. Spector Arachidonic acid cytochrome P450 epoxygenase pathway J. Lipid Res., April 1, 2009; 50(Supplement): S52 - S56. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Luo, Y. Zhou, H.-H. Chang, J. Zhang, T. Seki, C.-Y. Wang, E. W. Inscho, and M.-H. Wang Glomerular 20-HETE, EETs, and TGF-{beta}1 in diabetic nephropathy Am J Physiol Renal Physiol, March 1, 2009; 296(3): F556 - F563. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Minuz, H. Jiang, C. Fava, L. Turolo, S. Tacconelli, M. Ricci, P. Patrignani, A. Morganti, A. Lechi, and J. C. McGiff Altered Release of Cytochrome P450 Metabolites of Arachidonic Acid in Renovascular Disease Hypertension, May 1, 2008; 51(5): 1379 - 1385. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |